Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Immunostaining

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44332   clinical trials with a EudraCT protocol, of which   7365   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    25 result(s) found for: Immunostaining. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2022-003359-33 Sponsor Protocol Number: MABS06 Start Date*: 2023-06-21
    Sponsor Name:MUMC
    Full Title: Assess efficacy of intra-arterial autologous myogenic stem cell therapy for m.3243A>G mutation carriers
    Medical condition: Mitochondrial myopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10027710 Mitochondrial myopathy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-001788-19 Sponsor Protocol Number: ECS1479/2017 Start Date*: 2018-08-24
    Sponsor Name:Medical University Vienna
    Full Title: Metformin therapy to prohibit progression in patients with abdominal aortic aneurysm
    Medical condition: Abdominal aortic aneurysm
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001071-37 Sponsor Protocol Number: LUC19-001 Start Date*: 2019-08-06
    Sponsor Name:Cliniques Universitaires Saint-Luc
    Full Title: Open label, phase II, Proof of Concept study of neoadjuvant celecoxib in newly diagnosed patients with endometrial carcinoma Acronym: Celebrido
    Medical condition: Patients with confirmed primary endometrioid adenocarcinoma eligible for first line curative surgery
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-004223-36 Sponsor Protocol Number: CFEM345EGB05 Start Date*: 2005-07-29
    Sponsor Name:South Manchester University Hospital
    Full Title: Short term biological study effects of Zoledronate and Letrozole on invasive breast cancer
    Medical condition: Breast Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-001308-35 Sponsor Protocol Number: EB-UGI 01 Start Date*: 2006-05-04
    Sponsor Name:The Finsen Center, Rigshospitalet
    Full Title: A phase II study of erlotinib and bevacizumab in patients with advanced upper gastrointestinal carcinomas, refractory or intolerable to standard systemic therapy
    Medical condition: Histologically or cytologically verified upper gastro-intestinal carcinoma, including carcinomas of the esophagus, cardia, stomac, pancreas, gall bladder, and bile ducts of the following histologic...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2016-003774-40 Sponsor Protocol Number: TheStopGISTtrial Start Date*: 2016-11-09
    Sponsor Name:Oslo University Hospital
    Full Title: Discontinuation of imatinib in patients with oligo-metastatic gastrointestinal stromal tumor that has become radiologically undetectable with treatment
    Medical condition: Gastrointestinal stromal tumour (GIST)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10051066 Gastrointestinal stromal tumour PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Prematurely Ended) FI (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-000117-31 Sponsor Protocol Number: CAM-PLEX Start Date*: 2015-03-03
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge
    Full Title: To assess the safety of continuous IV administration of the CXCR4 antagonist, plerixafor (Mozobil), at potentially active plasma concentrations and assess its impact on the immune microenvironment ...
    Medical condition: Pancreatic adenocarcinoma High grade serous ovarian adenocarcinoma Colorectal adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033604 Pancreatic cancer LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-004239-35 Sponsor Protocol Number: 2017/16 Start Date*: 2019-09-26
    Sponsor Name:Centre Antoine Lacassagne
    Full Title: Randomized Phase II, 2-arm Study of Immunomodulation with Atezolizumab concomitant with High Dose Radiation (SBRT) Versus SBRT Alone in Patients with Oligometastatic Sarcomas
    Medical condition: Soft tissue sarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075333 Soft tissue sarcoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004554-42 Sponsor Protocol Number: TAMDMD Start Date*: Information not available in EudraCT
    Sponsor Name:University of Basel Children's Hospital, Division of Neuropediatrics
    Full Title: Tamoxifen in Duchenne muscular dystrophy: A multicenter, randomised, double-blind, placebo-controlled, phase 3 safety and efficacy 48-week trial Tamoxifen in Duchenne muscular dystrophy: A 48-week...
    Medical condition: Duchenne muscular dystrophy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: DE (Prematurely Ended) GB (GB - no longer in EU/EEA) FR (Completed) ES (Prematurely Ended) NL (Prematurely Ended) BE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-003212-22 Sponsor Protocol Number: 10MI30 Start Date*: 2013-06-03
    Sponsor Name:GOSH/ICH Joint Research & Development Office
    Full Title: Phase I study of ex-vivo lentiviral gene therapy for the inherited skin disease Netherton Syndrome
    Medical condition: Netherton Syndrome (NS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10062909 Netherton's syndrome PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000898-39 Sponsor Protocol Number: SSGXXII Start Date*: 2014-12-19
    Sponsor Name:Scandinavian Sarcoma Group
    Full Title: Three versus five years of adjuvant imatinib as treatment of patients with operable GIST with a high risk for recurrence: A randomised phase III study.
    Medical condition: gastrointestinal stromal tumor (GIST)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) FI (Trial now transitioned) SE (Trial now transitioned) ES (Ongoing) DK (Trial now transitioned) DE (Trial now transitioned) AT (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003585-27 Sponsor Protocol Number: GNS561CLIQ0211 Start Date*: 2018-01-11
    Sponsor Name:GENOSCIENCE PHARMA
    Full Title: Phase 1/2a study to evaluate the safety, activity, and pharmacokinetics of escalating doses of GNS561 in patients with primary or secondary liver cancer
    Medical condition: Hepatocellular carcinoma Intrahepatic cholangiocarcinoma Pancreatic adenocarcinoma with liver metastasis Colorectal cancer with liver metastasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    20.0 100000004864 10077738 Hepatocellular carcinoma metastatic LLT
    20.0 100000004864 10073077 Intrahepatic cholangiocarcinoma LLT
    20.0 100000004864 10033599 Pancreatic adenocarcinoma metastatic LLT
    20.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-003883-20 Sponsor Protocol Number: CSTI571JDE74 Start Date*: 2008-09-30
    Sponsor Name:Novartis Pharma GmbH
    Full Title: An open-label, multicenter, expanded access study of imatinib mesylate in adult patients with GIST in adjuvant setting after R0-resection
    Medical condition: gastrointestinal stromal tumors - adjuvant treatment after surgical tumor resection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051066 Gastrointestinal stromal tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) FR (Completed) IT (Completed) SK (Completed) CZ (Completed) BE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2016-000602-10 Sponsor Protocol Number: SNT-III-012 Start Date*: 2016-11-17
    Sponsor Name:Santhera Pharmaceuticals (Switzerland) Limited
    Full Title: A Phase III Double-blind, Randomized, Placebo-Controlled Study assessing the Efficacy, Safety and Tolerability of Idebenone in Patients with Duchenne Muscular Dystrophy Receiving Glucocorticoid Ste...
    Medical condition: Duchenne Muscular Dystrophy (DMD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: DE (Prematurely Ended) BE (Completed) NL (Prematurely Ended) SE (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) AT (Prematurely Ended) FR (Completed) IT (Prematurely Ended) IE (Completed) HU (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000701-21 Sponsor Protocol Number: CRAD001C2222 Start Date*: 2004-11-25
    Sponsor Name:Novartis Services AG
    Full Title: A phase 2, double-blind, randomized, placebo-controlled, multi-center study assessing the value of adding RAD001 to letrozole (Femara®) as preoperative therapy of primary breast cancer in postmenop...
    Medical condition: Systemic treatment for breast cancer given when the primary tumors are still present in situ within the breast can result in large tumors being down-staged, which can allow for more conservative su...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed) DE (Completed) GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-003592-19 Sponsor Protocol Number: NEOPAX-001 Start Date*: 2012-12-11
    Sponsor Name:CUB Erasme Hospital
    Full Title: Evaluation of tumoral perfusion modification by dynamic imaging after chemotherapy combining gemcitabine and nab-paclitaxel (Abraxane) in patients with potentially operable, locally advanced or met...
    Medical condition: Resectable (cohort 1) and locally advanced or metastatic (cohort 2) pancreatic ductal adenocarcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001853-15 Sponsor Protocol Number: NL61830 Start Date*: 2018-07-11
    Sponsor Name:Leiden University Medical Center
    Full Title: An explorative study for halting inflammation in patients with emphysema by intravenous administration of autologous bone marrow derived mesenchymal stromal cells.
    Medical condition: Pulmonary emphysema
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-020305-32 Sponsor Protocol Number: CRAD001CIT27T Start Date*: 2010-08-06
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: A phase II, open label study to evaluate the activity and safety of Everolimus in association to Imatinib in PDGFRA-D842V unresectable or metastatic gastrointestinal stromal tumours (GISTs)as...
    Medical condition: patients with unresectable and/or metastatic gastrointestinal stromal tumours with exon 18 PDGFRA mutation
    Disease: Version SOC Term Classification Code Term Level
    12.1 10051066 Gastrointestinal stromal tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-001710-37 Sponsor Protocol Number: NL73727 Start Date*: 2021-05-26
    Sponsor Name:Academisch Medisch Centrum
    Full Title: Intravenous immunoglobulin and prednisone vs. prednisone in newly diagnosed myositis: a double blind randomized clinical trial.
    Medical condition: idiopathic inflammatory myopathies
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-001267-33 Sponsor Protocol Number: A6181107 Start Date*: 2006-10-11
    Sponsor Name:Pfizer Pharma GmbH
    Full Title: Phase III Randomized, Multi Center Study of Sunitinib Malate (SU 011248) or Capecitabine in Subjects with Advanced Breast Cancer who failed both a taxane and an anthracycline chemotherapy regimen o...
    Medical condition: Histologically or cytologically proven diagnosis of breast adenocarcinoma that is not amenable to surgery, radiation, or combined modality therapy with curative intent
    Disease: Version SOC Term Classification Code Term Level
    9.1 10055113 Breast cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended) FR (Completed) IT (Prematurely Ended) GB (Completed) BG (Completed) ES (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA